このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Milestone Scientific マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Arjan Haverhals

最高経営責任者

US$680.3k

報酬総額

CEO給与比率	51.5%
CEO在任期間	3.8yrs
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	5.3yrs

経営陣の近況

Recent updates

Did You Miss Milestone Scientific's (NYSEMKT:MLSS) Whopping 317% Share Price Gain?

Feb 23

Here's What Milestone Scientific Inc.'s (NYSEMKT:MLSS) Shareholder Ownership Structure Looks Like

Dec 15

Earnings Update: Here's Why Analysts Just Lifted Their Milestone Scientific Inc. (NYSEMKT:MLSS) Price Target To US$4.00

Nov 19

CEO報酬分析

Milestone Scientific の収益と比較して、Arjan Haverhals の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$7m
Dec 31 2023	US$680k	US$350k	-US$7m
Sep 30 2023	n/a	n/a	-US$7m
Jun 30 2023	n/a	n/a	-US$7m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$841k	US$350k	-US$9m
Sep 30 2022	n/a	n/a	-US$8m
Jun 30 2022	n/a	n/a	-US$8m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$735k	US$319k	-US$7m
Sep 30 2021	n/a	n/a	-US$7m
Jun 30 2021	n/a	n/a	-US$6m
Mar 31 2021	n/a	n/a	-US$7m
Dec 31 2020	US$359k	US$157k	-US$7m

報酬と市場: Arjanの総報酬 ($USD 680.27K ) は、 US市場 ($USD 673.68K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Arjanの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Arjan Haverhals (62 yo)

3.8yrs

在職期間

US$680,265

報酬

Mr. Jan Adriaan Haverhals, also known as Arjan, serves as Chief Executive Officer and Director at Milestone Medical, Inc. since June 2021 and 2023 respectively. Mr. Haverhals has been President of Mileston...

取締役

名称	ポジション	在職期間	報酬	所有権
Jan Haverhals	President	1.5yrs	US$680.27k	データなし
Leonard Osser	Founder & Vice Chairman	33yrs	US$100.00k	3.7% $ 1.9m
Neal Goldman	Independent Chairman of the Board	5.3yrs	US$120.00k	2.84% $ 1.4m
Paul Davis	Member of Scientific Advisory Board	no data	データなし	データなし
Benedetta Casamento	Independent Director	2.3yrs	US$120.00k	0.35% $ 178.0k
Ralf Gebhard	Member of Scientific Advisory Board	no data	データなし	データなし
Lorrence Green	Member of Scientific Advisory Board	no data	データなし	データなし
Gian Trombetta	Independent Director	10.2yrs	US$100.00k	13.11% $ 6.7m
Michael McGeehan	Independent Director	6.8yrs	US$110.00k	0.65% $ 333.6k
Olivier Choquet	Member of Scientific Advisory Board	no data	データなし	データなし
Didier Demesmin	Independent Director	less than a year	データなし	データなし

5.3yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: MLSSの取締役会は経験豊富であると考えられます ( 5.2年の平均在任期間)。

Milestone Scientific マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Milestone Scientific Inc., Annual General Meeting, Jul 16, 2024

Director notifies of intention to sell stock

Less than half of directors are independent

Milestone Scientific Inc. Appoints Didier Demesmin to Board of Directors

Milestone Scientific Inc. Announces Resignation of Peter J. Milligan as Chief Financial Officer, Effective September 1, 2023

Milestone Scientific Inc. Announces the Appointment of Peter Milligan as the Chief Financial Officer

Recent updates

Milestone Scientific Receives Regulatory Approval to Market Compuflo Epidural System in Brazil

Milestone Scientific Inc., Annual General Meeting, Jul 16, 2024

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates decrease by 10%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Milestone Scientific Inc. has completed a Follow-on Equity Offering in the amount of $3.00195 million.

New minor risk - Shareholder dilution

Milestone Scientific Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates decrease by 13%

New major risk - Financial position

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Director notifies of intention to sell stock

Less than half of directors are independent

Milestone Scientific Inc. Appoints Didier Demesmin to Board of Directors

Milestone Scientific Inc. Announces Resignation of Peter J. Milligan as Chief Financial Officer, Effective September 1, 2023

Consensus EPS estimates fall by 29%, revenue upgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Consensus estimates of losses per share improve by 12%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Milestone Scientific Inc. Announces the Appointment of Peter Milligan as the Chief Financial Officer

Milestone Scientific Inc. Announces Board Changes

Milestone Scientific Inc. Appoints Neal Goldman as Chairman of the Board of Directors

Leonard M. Schiller Tenders His Resignation to Milestone Scientific Inc. as A Director

Insufficient new directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Milestone Scientific Inc. Reports Commencement of Sales of its CompuFlo(R) Epidural Instrument Disposables at a Leading Veterinary and Academic Institution

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Insufficient new directors

Milestone Scientific Inc., Annual General Meeting, Jun 13, 2022

Price target decreased to US$4.00

Price target decreased to US$4.00

Founder notifies of intention to sell stock

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Founder notifies of intention to sell stock

Milestone Scientific Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Founder exercised options to buy US$268k worth of stock.

Third quarter 2021 earnings released: US$0.029 loss per share (vs US$0.023 loss in 3Q 2020)

Founder exercised options to buy US$417k worth of stock.

Independent Chairman of the Board notifies of intention to sell stock

Independent Chairman of the Board recently sold US$86k worth of stock

Consensus EPS estimates fall to -US$0.11

Second quarter 2021 earnings released: US$0.039 loss per share (vs US$0.056 loss in 2Q 2020)

Chief Financial Officer Scott Kahn has left the company

Milestone Scientific Inc.(NYSEAM:MLSS) dropped from Russell 3000E Value Index

Consensus forecasts updated

First quarter 2021 earnings released: US$0.015 loss per share (vs US$0.032 loss in 1Q 2020)

Consensus revenue estimates increase to US$10.3m

Full year 2020 earnings released: US$0.12 loss per share (vs US$0.17 loss in FY 2019)

Milestone Scientific Receives Notice of Allowance for European Patent Related to Combination of Nerve Stimulation and Dps Dynamic Pressure Sensing Technology® to Optimize Needle Tip Location in Ultrasound-Guided Pnb Procedures

Milestone Scientific Inc. Commences Sales of CompuFlo® / CathCheck™ Disposables to the Nationally Recognized Medical University of South Carolina

New 90-day high: US$4.13

Did You Miss Milestone Scientific's (NYSEMKT:MLSS) Whopping 317% Share Price Gain?

Independent Chairman of the Board notifies of intention to sell stock

Analysts update estimates

Independent Chairman of the Board recently sold US$169k worth of stock

Milestone Scientific Inc. Adds Three Additional Premier Distributors Providing Robust U.S. Coverage and A New Distributor in Canada for the Company’S Dental Instrument

Milestone Scientific Inc. Signs Two Additional Distribution Agreements with Atlanta Dental and Nashville Dental for its Wand Single Tooth Anesthesia System

New 90-day high: US$3.48

Director recently sold US$215k worth of stock

Milestone Scientific Inc. Receives Notice of Allowance for U.S Patent Related to Compuflo® Disposables

New 90-day high: US$2.90

Milestone Scientific Inc. Announces It Has Begun Implementing Three-Year Strategy to Expand the World-Wide Global Dental Market

Milestone Scientific Inc. Announces Agreement with Bitmedical AG to Distribute the CompuFlo® Epidural Instrument Across Austria and Switzerland

Milestone Scientific Inc. Raises Revenue Guidance for Fourth Quarter 2020

Founder exercised options to buy US$183k worth of stock.

マネジメント基準チェック /34